Introduction In 2020, prior to COVID-19 vaccine rollout, the Brighton Collaboration created a
priority list, endorsed by the World Health Organization, of potential adverse events relevant …

SARS-CoV-2 vaccination offered the opportunity to emerge from the pandemic and, thereby,
worldwide health, social, and economic disasters. However, in addition to efficacy, safety is …

The SARS-CoV-2 vaccination campaign is probably one of the most historic public hygiene
measures in modern medicine. The drama of the pandemic has forced the scientific …

Background Vaccine‐associated anaphylaxis is a rare but life‐threatening reaction that
occurs within minutes to hours of exposure to allergens. As studies utilizing large‐scale data …

A worldwide COVID-19 mass vaccination campaign targeting adults was launched in late
December 2020. Subsequently, the Comirnaty (BNT162b2) vaccine was recommended for …

Background: COVID-19 continues to present challenges in the care of older adults with
frailty and/or comorbidities and very old patients, who can be hospitalized with severe …

Background Data on allergic reactions after the administration of coronavirus disease
(COVID-19) vaccines are limited. Our aim is to analyze reports of allergic reactions after …

Background Oral adverse events (AEs) following COVID-19 vaccination have been
sporadically reported during the previous months, warranting further investigation for their …

COVAX, the international initiative supporting COVID-19 vaccination campaigns globally, is
budgeted to be the costliest public health initiative in low-and middle-income countries, with …

Background: The earliest cases of Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) emerged in Wuhan, China, in December 2019. Since the declaration as a …